UnitedHealthcare sued by shareholders over reaction to CEO’s killing

UnitedHealthcare sued by shareholders over reaction to CEO’s killing


Brian Thompson, CEO of UnitedHealthcare.

Courtesy: UnitedHealth Group

A group of investors sued UnitedHealthcare Group on Wednesday, accusing the company of misleading them after the killing of its CEO, Brian Thompson.

The class action lawsuit — filed in the Southern District of New York — accuses the health insurance company of not initially adjusting their 2025 net earning outlook to factor in how Thompson’s killing would affect their operations.

On Dec. 3 — a day before Thompson was fatally shot — the company issued guidance that included net earnings of $28.15 to $28.65 per share and adjusted net earnings of $29.50 to $30.00 per share, the suit notes. And on January 16, the company announced that it was sticking with its old forecast.

The investors described this as “materially false and misleading,” pointing to the immense public scrutiny the company and the broader health insurance industry experienced in the wake of Thompson’s killing.

The group, which is seeking unspecified damages, argued that the public backlash prevented the company from pursuing “the aggressive, anti-consumer tactics that it would need to achieve” its earnings goals.

“As such, the Company was deliberately reckless in doubling down on its previously issued guidance,” the suit reads.

The company eventually revised its 2025 outlook on April 17, citing a needed shift in corporate strategy — a move that caused its stock to drop more than 22% that day.

UnitedHealthcare did not immediately return a request for comment on Thursday.

Thompson’s fatal shooting on the streets of New York City in broad daylight sent shockwaves across the nation.

Luigi Mangione, the 27-year-old man accused of the killing, has pleaded not guilty to federal and state charges against him. The legal defense fund for Mangione surpassed the $1 million mark in donations on Tuesday.





Source

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Health

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. I’m back in New […]

Read More
Hims & Hers to acquire European telehealth platform in global expansion
Health

Hims & Hers to acquire European telehealth platform in global expansion

The Hims logo arranged on a smartphone in New York, US, on Wednesday, Feb. 12, 2025.  Bloomberg | Bloomberg | Getty Images Hims & Hers Health announced Tuesday it will acquire European telehealth platform Zava in its push to expand globally. “We’re excited to take this moment to really accelerate both the European expansion, but […]

Read More
Speaker Mike Johnson says some Medicaid recipients will ‘choose’ whether to lose healthcare under House spending bill
Health

Speaker Mike Johnson says some Medicaid recipients will ‘choose’ whether to lose healthcare under House spending bill

Speaker Mike Johnson, R-La., on Sunday defended cuts to Medicaid in the budget bill House Republicans passed last month from allegations that millions of Americans could lose their access to the program, saying that “4.8 million people will not lose their Medicaid unless they choose to do so.” Johnson told NBC News’ “Meet the Press” that the […]

Read More